Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

This study has been terminated.

Study NCT00179699 Information provided by Celgene Corporation

First Received: September 10, 2005 Last Updated: November 2, 2005 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been terminated.
Estimated Study Completion Date:	November 2006
Estimated Primary Completion Date:	No date given